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Introduction: Skeletal metastases can weaken the bone, necessitating surgery, and surgical treatment
options vary. The aim of this study was to investigate the revision rate of reconstructions in surgically
treated diaphyseal skeletal metastases.
Materials and methods: Between 2000 and 2018 at Helsinki and Tampere university hospitals in Finland,
a total of 164 cases with diaphyseal skeletal metastases were identified from a prospectively maintained
database. Tumor location was humerus, femur, and tibia in 106 (65%), 53 (32%), and 5 (3.0%) cases,
respectively. A total of 82 (50%) cases were treated with intramedullary nailing (IMN), 73 (45%) with IMN
and cementation, and 9 (5%) with another technique.
Results: In the upper extremity, implant survival (IS) was 96.4% at 1, 2, and 5 years; in the lower ex-
tremity, it was 83.8%, 69.1%, and 57.6% at 1, 2, and 5 years, respectively. Lower extremity IS for impending
lesions was 100% at 1, 2, and 5 years, and in cases operated for true pathologic fracture, it was 71.6%,
42.9%, and 21.5% at 1, 2, and 5 years, respectively. In IMN cases without cement, the complication rate was
16% (13/82) when compared to 6% (4/73) in IMN cases with cementation.
Discussion: We would advocate for early intervention in patients with metastatic bone disease affecting
the femur rather that watchful waiting with the risk for fracture and the need for urgent intervention.
However, this choice must be balanced against the underlying risk of surgical intervention in a poten-
tially fragile population with often limited prognoses.
© 2019 Published by Elsevier Ltd.Introduction
Skeletal metastases are the most common destructive bone
conditions encountered by orthopedic oncologists. In patients with
disseminated cancer, bone is the third most common site of met-
astatic disease after the lung and the liver. In the appendicular






the most common primary cancer is breast followed by lung,
prostate, renal cell carcinoma (RCC), and thyroid cancer [2]. As the
incidence of cancer and survival of disseminated cancer patients
has increased, so has the incidence of skeletal-related events
involving metastasis [3].
Metastatic lesions can weaken the bone and may require sur-
gery. The indications for surgery of long bone metastases are
intractable pain and an impending or actual pathologic fracture [2].
Surgical indications differ among regions; 75% of surgeries for
skeletal metastasis treatment in the United States are performed
for impending fracture, but in Scandinavian countries, impending
fracture was the indication for only 18% of the cases [4,5]. There is
no consensus on the definition of impending fracture. Impending
fracture refers to the state of a bone where a pathological fracture
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scoring systems have been developed, including Mirels' scoring
system [6], Harrington's criteria [7] and scoring from van der
Linden at al [8]. However, there is currently no definite and valuable
tool that can be used universally to objectively quantify the risk [9].
Because skeletal metastases almost always indicate that the disease
is incurable, surgery for skeletal metastases is palliative, with the
main purpose of stabilizing the bone and preserving the patient's
independence through immediate functional restoration in a single
procedure, without need for revision surgery [2,10e12].
Most procedures performed for skeletal metastases are in the
metaphyseal area. The management of metaphyseal metastases
varies, and most surgeons treat these patients according to their
own preferential standard practice for pathologic fractures [2].
Surgical alternatives to metaphyseal metastases range from stabi-
lization with an intramedullary nailing (IMN) to resection and
endoprosthetic reconstruction (EPR), depending on estimated
survival, because the device chosen should last the remainder of
the patient's life [13].
Diaphyseal metastases in the bone are less common, repre-
senting only approximately 20% of surgically treated skeletal me-
tastases [1]. Surgical alternatives are limited, and nailing offers a
simple, relatively quick and inexpensive solution, permitting im-
mediate delivery of radiotherapy without the risk of wound
compromise. With time, however, intramedullary nails carry a risk
of failure. Because of tumor growth or radiotherapy, pathologic
fractures do not heal, healing takes too much time, or healing takes
place with an insufficient bone callus. Cement augmentation is
used for additional mechanical stability of the fixation and is re-
ported to decrease mechanical failure of the implants [13e15].
Because of the rarity of pathologic fractures of diaphyseal me-
tastases, however, information is lacking in this field. To our
knowledge, no groups have reported the outcome and revision rate
of surgically treated diaphyseal skeletal metastases. Therefore, the
aims of this study were to (i) investigate the implant survival (IS) of
reconstructions, (ii) present complication rates, and (iii) investigate
patient survival in surgically treated diaphyseal skeletal metastases.
Material and methods
Study design
This multi-center retrospective study included 164 fractures or
impending fractures. Following institutional ethical review board
approval, patients who were diagnosed and surgically treated for a
metastatic long-bone diaphyseal lesion in the diaphyseal area of
thick cortical bone between January 2000 and January 2018 at the
Helsinki University Hospital, Helsinki, Finland, and Tampere Uni-
versity Hospital, Tampere, Finland, were identified from prospec-
tively maintained databases. All the other anatomical locations,
including metaphyseal area, were excluded. Details of the collected
data included the primary tumor, site, type of operation (IMN,
plate-screw fixation, EPR, or a combination), fracture type
(impending or true pathologic fractures), metastatic load, sex, age,
complications, and oncological and surgical outcomes, including
patient survival and IS. IS was defined as revisions for any reason as
the final result. Impending fracture was considered when patient
had a painful medullary lytic lesion resulting a significant reab-
sorption of the cortical thickness, defined by the experienced
surgeon.
Demographics
A total of 164 procedures were performed in 146 patients. The
study comprised 67 (41%) men and 97 (59%) women with a meanage of 70 years (range, 38e94) at the time of surgery. The primary
tumor was breast cancer in 50 (30.5%), myeloma in 32 (19.5%), lung
cancer in 21 (12.8%), RCC in 19 (11.6%), prostate cancer in 16 (9.8%),
and other in 26 (15.8%) cases. Of the 164 lesions, 106 (65%) were in
the humerus, 53 (32%) in the femur, and 5 (3%) in the tibia. Nine
(6%) cases were solitary synchronous skeletal metastases. In 31
cases (19%), reconstruction was undertaken for impending fracture
indicated by significant bone destruction, intractable pain, and loss
of function, and in 129 (79%) cases for true pathologic fracture. In 4
(2%) cases, data were missing.
The mean lag time from diagnosis of the primary malignancy to
diagnosis of skeletal metastases was 46 months (range, 0e396).
The mean lag time from diagnosis of skeletal metastases to surgery
of metastases was 18 months (range, 0e241). Mean follow-up was
12.4 months (range, 0e184). A total of 83% (121/145) of the patients
died during follow-up, and 47% (68/145) died within 6months after
surgery. Patient characteristics are summarized in Table 1.
Surgical procedures
A total of 61 cases (37%) were operated in the Helsinki University
Hospital and 103 cases (63%) in the Tampere University Hospital, in
Finland. Procedures were performed by orthopedic oncologists
(orthopedic surgeon been specialized in the treatment of bone
tumors) or experienced orthopedic surgeons (minimum of five
years’ experience).
Depending on the site of the metastatic lesion, different surgical
procedures were used. Diaphyseal lesions were treated by long
static IMN with or without cementation, plate-screw fixation, or
EPR. The implant used and the use of cement was based on surgeon
preference. In femur, only long intramedullary nails were used. In
all cases of IMN fixation without cementation, nails were locked in
static mode. Postoperative care and rehabilitation varied among
patients, depending on their health status, but with the goal of
weight-bearing as tolerated.
In the humerus, the operative method was IMNwithout cement
in 41 cases (39%), IMN with cement in 59 cases (56%), osteosyn-
thesis with plate fixation in 4 cases (4%), and EPR in 2 cases (2%). In
femur, IMN without cement was used in 39 patients (74%), IMN
with cement in 11 patients (21%), and EPR in 3 cases (6%). In tibia, 2
cases were treated with IMN without cement and 3 cases with IMN
with cement. In femur and humerus, the reason for surgery was an
impending fracture in 21 of 51 (41%) and in 8 of 104 (8%), respec-
tively. In 4 cases, the data were missing.
Statistical analysis
Descriptive statistics were used to present the demographic
data, and the KaplaneMeier method was applied for patient and IS.
Survival rates were calculated from the date of surgery to the most
recent follow-up, death, or IS to revision surgery. Univariate anal-
ysis was performed by comparing groups with the log-rank test
with subsequent multivariate Cox proportional hazard analysis of
significant variables to identify independent predictors of patient
survival or IS. The Chi-square test or Fisher's exact test was used to
compare variables between groups and the KruskaleWallis test for
means between groups. A p-value <0.05 was considered signifi-
cant. Statistical analysis was done using SPSS Statistics 23.0 (IBM,
New York, USA).
Results
Overall IS was 91.5% (95% confidence interval (CI), 85%e98%) at 1
year, 81.9% (95% CI, 68%e96%) at 2 years, and 74.4% (95% CI, 56%e
93%) at 5 years (Fig. 1). When stratified by location, in the upper
Table 1
Characteristics of cases (values are presented in number of cases).
Characteristics Total Nailing Nailing with cement Other





Humerus 106 (64.6%) 41 (38.7%) 59 (55.7%) 6 (5.7%)
Femur 53 (32.3%) 39 (73.6%) 11 (20.8%) 3 (5.7%)
Tibia 5 (3.0%) 2 (40.0%) 3 (60.0%) e
Mean follow-up months (range) 12.4 (0e184) 15.4 (0e184) 9.8 (0e74) 7.2 (0e25)
Age at surgery years (range) 70 (38e94) 69 (38e88) 70 (41e94) 72 (42e85)
Pathologic fracture
Present 129 (78.7%) 54 (41.1%) 69 (53.5%) 7 (5.4%)
Urgent 31 (18.9%) 25 (80.6%) 4 (12.9%) 2 (6.5%)
Data missing 4 (2.4%)
Bone metastasis
Solitary 9 (5.5%) 5 (55.6%) 4 (44.4%) 0 (0%)
Multiple 151 (92.1%) 73 (48.3%) 69 (45.7%) 9 (5.9%)
Data missing 4 (2.4%)
Pulmonary metastasis
Yes 42 (25.6%) 17 (40.5%) 23 (54.8%) 2 (4.8%)
No 122 (74.6%) 65 (53.3%) 50 (41.0%) 7 (5.8%)
Liver metastasis
Yes 21 (12.8%) 7 (33.3%) 12 (57.1%) 2 (9.6%)
No 143 (87.2%) 75 (52.4%) 61 (42.7%) 7 (4.9%)
Preoperative radiotherapy
Yes 20 (12.2%) 5 (25.0%) 14 (70.0%) 1 (5.0%)
No 144 (87.8%) 77 (53.5%) 59 (41.0%) 8 (5.6%)
Postoperative radiotherapy
Yes 59 (36.0%) 31 (52.5%) 26 (44.1%) 2 (3.4%)
No 105 (64.0%) 51 (48.6%) 47 (44.8%) 7 (6.7%)
Primary tumor
Breast 50 (30.5%) 26 (52.0%) 21 (42.0%) 3 (6.0%)
Myeloma 32 (19.5%) 16 (50.0%) 16 (50.0%) e
Lung 21 (12.8%) 12 (57.1%) 8 (38.1%) 1 (4.8%)
Renal cell 19 (11.6%) 8 (42.1%) 9 (47.4%) 2 (10.5%)
Prostate 16 (9.8%) 8 (50.0%) 8 (50.0%) e
Other 26 (15.8%) 12 (46.2%) 11 (42.3.0%) 3 (11.5%)
Dead at follow-up
Yes 138 (84.1%) 65 (47.1%) 67 (48.6%) 6 (4.4%)
No 26 (15.9%) 17 (65.4%) 6 (23.1%) 3 (11.5%)
Pulmonary embolism
Yes 6 (3.7%) 5 (6.1%) 0 (0%) 1 (11.1%)
30 days mortality rate
25 (15.2%) 13 (15.9%) 10 (13.7%) 2 (22.2%)
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extremity, the IS was 83.8% at 1 year, 69.1% at 2 years, and 57.6% at 5
years (p¼ 0.008) (Fig. 2). Radiotherapy given either pre- or post-
operatively was not a significant factor in IS (p¼ 0.860).
There was no statistically significant difference between IMN
with or without cement when all locations were combined. The IS
for IMN without cement as a surgical method was 87.7% at 1 year,
81.8% at 2 years, and 72.2% at 5 years. When the surgical method
was IMNwith cement, the IS was 95.0% at 1 year and 76.0% at 2 and
5 years (p¼ 0.329).
Upper extremity
In upper extremity, the IS was better in the group treated with
IMN and cement when compared to the group treated with IMN
without cement. IS for IMN without cement was 91.1% at 1, 2, and 5
years, and for IMN with cement, it was 100% at 1, 2, and 5 years,
respectively (p¼ 0.112) (Fig. 3).
Lower extremity
In lower extremity, the IS was better in the group treated forimpending fracture compared to the true pathologic fractures.
Lower extremity IS for impending lesions was 100% at 1, 2, and 5
years, whereas the IS for cases operated for true pathologic fracture
was 71.6%, 42.9%, and 21.5% at 1, 2, and 5 years, respectively
(p¼ 0.017; Fig. 4). The use of cement was not a significant factor in
lower extremity IMN for increasing IS (p¼ 0.895).Complications and revision
The overall complication rate was 12% (18/155) in all IMN cases.
In IMN cases without cement, the complication rate was 16% (13/
82), compared to 6% (4/73) when cement was used, and the dif-
ference was statistically significant (p¼ 0.03). The complication
rate was 9% (9/100) in all upper extremity IMN cases. In the non-
cemented group, the complication rate was 17% (7/41) in compar-
ison to 3% (2/59) in the cemented group (p¼ 0.014). Complications
are summarized in Table 2.
All upper extremity revisions were performed in patients
treated with IMN without cement. All lower extremity revisions
were performed in patients who were primarily operated for true
pathologic fracture.
Fig. 1. Overall implant survival.
Fig. 2. Upper and lower extremities' implant survival.
Fig. 3. Upper extremity implant survival. Intramedullary nailing with or without
cement.
Fig. 4. Implant survival in patients with urgent or present pathologic fracture.
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Overall patient survival was 35.5% at 1 year, 11.1% at 2 years, and
2.7% at 5 years. In univariate analysis, significant factors affecting
overall patient survival were pulmonary metastases (p¼ 0.042),
sex (p¼ 0.004), primary cancer (p¼ 0.003), complication
(p¼ 0.007), and revision surgery (p¼ 0.002). Female sex and breastcancer positively affected patient survival. Pathologic fracture,
when compared to impending fracture, was not a significant factor
in overall survival (p¼ 0.262).
Revision surgery remained a positive significant factor for
overall patient survival (hazard ratio, 0.312; 95% CI, 0.132e0.740;
p¼ 0.008), in multivariate analysis. The median survival time after
the operation was 6 months (range, 0e184 months; mean, 21
Table 2
Complications of the cases.
Characteristics Osteosynthesis problems Tumor progression Infection Fracture in other part of the same bone
Location
Humerus 5 2 1 1
Femur 5 3 e 1
Tibia e 1 e e
Operation
I 8 4 1 e
IC 2 2 e e
Pathologic fracture
Present 10 5 e 1
Urgent 1 e 1 e
I ¼ Intramedullary nailing without cementation.
IC ¼ Intramedullary nailing with cementation.
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(range, 0.1e74; mean, 16) months in myeloma, 11 (range, 0.2e185;
mean,17)months in breast cancer, 2 (range, 0e14;mean, 3)months
in lung cancer, and 5 (range, 0.4e51; mean, 11) months in prostate
cancer.
Discussion
As the biological healing of pathologic diaphyseal fractures is
not to be relied on, the goal of treatment in skeletal metastases with
pathologic fractures is to stabilize the lesions, regain patient
mobility, and maintain the highest possible quality of life with a
low revision risk. Our retrospective, multi-center study aimed to
assess the prognostic factors influencing IS, complication rate, and
patient survival for the treatment of diaphyseal skeletal metastases.
In noneweight-bearing extremities like the humerus, the
method of surgical choice, according to the literature, does not
seem to play an important role [12]; IMN [14,15] and open reduc-
tion with plate fixation [16] yield similar results and are both
popular among surgeons. Plating has potentially more problems
because implant choice, wound problems, and tumor progression
might, in inexperienced hands, lead to failure, whereas nailing is
more secure. The literature suggests advantages and disadvantages
for both methods [2,17e21], but the more interesting question is
the role of cement augmentation.
In our current study, in humerus, IS for IMNwithout cement was
91.1% at 1, 2, and 5 years, and IMNwith cement was 100% at 1, 2, and
5 years, respectively. Our group has previously shown that nailing
with cement augmentation reduces postoperative pain, as has been
also shown by Kim et al. In their study, they could confirm that
cement augmentation not only gives better pain relief but also
decreases disease progression [14,22]. Even though, the difference
in IS in humerus between IMN with or without cement did not
reach statistical significance, we did observe a statistically signifi-
cant difference in the rate of complications between these groups.
The difference in the rate of revisions was most likely because the
indication for revision surgery in upper extremities among these
fragile patients is high. Therefore, based on our current study, in
agreement with the literature, we recommend using cement aug-
mentations in IMN when treating humeral diaphyseal pathologic
fractures [14,22].
The question of when to stabilize long bone metastases,
particularly those of the femur, remains a challenge. The results
presented here differ from those reported previously demon-
strating an advantage of IMNwith cement augmentation compared
to unaugmented IMN [22]. This finding may be confounded by the
high number of patients with metastatic lung carcinoma included
in Kim et al.‘s study, a tumor type with a known poor prognosis
in the presence of metastatic disease, and the proportion ofimpending fractures was not reported [23].
We have demonstrated a significant improvement in IS when
IMN is applied to impending fracture at 1, 2, and 5 years, as
compared to IMN for established pathological fracture. The IS in the
complete fracture group was not improved by augmentation of
fixation with cement. Actual pathologic fracture appears to make
the bone very unstable and difficult to stabilize with IMN with or
without cement. The poor-quality bone from disease infiltration
will also contribute to the difficulty in fracture reduction and sta-
bilization and subsequently lead to implant failure.
Conventional wisdom would suggest careful observation for
impending pathological fracture, applying universally accepted
though unvalidated scoring systems such as the Mirel's score, to
quantify the risk of subsequent fracture [24]. Our findings suggest
that early intervention for metastatic lesions of the femur results in
a reduction in subsequent fracture and implant failure with a
concurrent effect on quality of life for patients, many of whom are
undergoing palliative treatment for advanced metastatic disease.
IMN is not without risk, and of course, an earlier intervention for
such lesions would expose a number of patients to the risks of
surgery, in whom no intervention might ever be required either
because of mortality from advanced disease or successful systemic
treatment of the underlying malignancy. Intramedullary stabiliza-
tion is not without risk, either, particularly when applied to pa-
tients with underlying malignancy and exposed to its potential
toxic effects [25e28]. Rather than advocate IMN of any pathological
femoral lesion, we would, however, advocate a more careful
assessment of patients on a case-by-case basis, taking into
consideration the chemo- and radiosensitivity of the primary tu-
mor, the projected life expectancy of the patient, and the informed
wishes of the patient and their family.
One potential criticism of our findings is that the two groups
differed in terms of their underlying diagnoses and demographics,
the use of radiotherapy, and the definitions of impending fracture.
It should be noted, however, that there were no differences in the
underlying diagnoses and demographics of the two groups, and
diaphyseal metastases were hardly ever solitary. Also, all cases
were assessed for the risk of fracture by the two senior authors, and
bias in this respect thus could be excluded.
One of the main goals in treating diaphyseal pathological lesions
is to minimize the risk of complications and further revision sur-
gery. The present study shows that the overall complication rate
was 12%, which is in concordancewith current literature, where the
rate of complications has been reported to vary from 2 to 22%
[2,20,21,29]. Our study also showed that complication or revision
surgery is a significant factor in increasing overall survival. We
believe that complication or revision surgery does not improve
survival but is merely a sign of patient selection because patients
with better overall survival mobilize better and with the time
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metastasis, including renal cell carcinoma, are hypervascular and
carry a risk of massive blood loss. Postoperative embolization is
often used to reduce intraoperative blood loss [30].
Once a diagnosis of skeletal metastases is made, the disease is
considered incurable, although some patients might live several
years. In our study, the overall patient survival rates were 35.5%,
11.1%, and 2.7% at 1, 2, and 5 years, respectively. We also demon-
strated that half of the patients lived less than 6 months after
surgery. Our results are in accordance with the current literature of
overall survival after surgery for pathologic fracture [25,31,32].
Disease-specific significant factors for decreasing survival, as indi-
cating developed disease, were pulmonary metastases, sex, and
primary cancer. Female sex and breast cancer increasingly affected
patient survival. The significant difference in sex and the primary
tumor is related to female sex and breast cancer, providing the
great majority of cases that warranted orthopedic intervention.
Breast cancer patients have improved survival as in the population-
based study, 52% of breast cancer patients were alive at 1 year after
diagnosis of skeletal metastases and 26% after 3 years [31].
Our study had limitations. First, it is a retrospective study lack-
ing any randomization. Second, we did not have any patient-related
outcome measures for analyzing patient-related quality of life or
functional outcome. Nevertheless, to our knowledge, this is the
largest dataset that has been published. The strengths of the pre-
sent study were a relatively large patient cohort and the possibility
of collecting full data, thanks to our united health care system,
where all patients and complications are treated in the same unit
throughout the disease.
In conclusion, patient selection is always an important influ-
encing factor and is more compelling particularly in patients with
metastatic disease with limited physiological reserve. The assess-
ment for a suitable surgical method becomes important because
patient survival must be compared to a possible prophylactic pro-
cedure and the method of surgery. In locations like the proximal
femur, where surgical options are more diverse, the estimated
survival has more impact on implant selection. In diaphyseal me-
tastases, however, surgical options are scarce, and although this
study did not specifically address the results of revision surgery, all
of the intercalary prosthesis cases were unsuccessful when used as
a revision solution to treat a failed IMN; therefore, good alternatives
to nailing are lacking. In the upper extremity, a well-tolerated
method with a low complication risk is IMN with cement
augmentation. In the lower extremity, prophylactic IMN appears to
have a low complication and revision risk. The indication for pro-
phylactic IMN is, however, undefined because burdensome over-
treatment with these fragile patients should be avoided. Patients
with short survival and actual pathologic fracture can be treated
with IMN with or without cement augmentations, but the best
surgical method for patients with actual lower extremity patho-
logical fracture and long survival remains unsolved and needs
further study.
Conclusion
We advocate early intervention for patients with metastatic
bone disease affecting the femur rather thanwatchful waiting with
the risk for fracture and the need for urgent intervention. However,
this choice must be balanced by the underlying risk of surgical
intervention in a potentially fragile population with often limited
prognoses.
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